| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.10. | Glucotrack, Inc. - 8-K, Current Report | 18 | SEC Filings | ||
| 22.10. | Glucotrack Announces 1-for-2 Reverse Stock Split | 1 | RTTNews | ||
| 22.10. | Glucotrack, Inc. Announces Reverse Stock Split | 68 | Business Wire | 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack"... ► Artikel lesen | |
| 19.10. | Glucotrack, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 14.10. | Glucotrack, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 28.09. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.09. | GlucoTrack Stock Rises 27% After Public Offering Announcement | 2 | RTTNews | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 24.09. | Glucotrack prices $3.1M public offering | 3 | Seeking Alpha | ||
| 24.09. | Glucotrack prices $3.1 million public offering at $2.04/share | 1 | Investing.com | ||
| 24.09. | Glucotrack platziert öffentliches Angebot über 3,1 Millionen US-Dollar zu 2,04 US-Dollar je Aktie | 2 | Investing.com Deutsch | ||
| 18.09. | Glucotrack: Direktor Paul V. Goode tritt wegen möglichem Interessenkonflikt zurück | 4 | Investing.com Deutsch | ||
| 18.09. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.09. | Glucotrack, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 11.09. | Glucotrack announces $11.5M financing | 1 | Seeking Alpha | ||
| 11.09. | Glucotrack secures $11.5M in convertible note financing | 1 | Investing.com | ||
| 09.09. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Glucotrack announces 1-for-15 reverse stock split | 1 | Seeking Alpha | ||
| 27.08. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.08. | Glucotrack, Inc. Announces Reverse Stock Split | 331 | Business Wire | 1-for-15 reverse stock split to become effective as of the opening of trading on August 31, 2026
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack"... ► Artikel lesen | |
| 19.08. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,000 | +4,56 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler Erhält GMP-Zertifizierung für Actinium-225 | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Zulassungsgenehmigung
Eckert & Ziegler Erhält GMP-Zertifizierung für Actinium-225
28.10.2026 / 14:00 CET/CEST
Für den... ► Artikel lesen | |
| TELADOC HEALTH | 8,496 | +7,00 % | Teladoc Health, Inc.: Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 | ||
| SERNOVA BIOTHERAPEUTICS | 0,067 | -4,03 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics
07.09.2026 / 09:31 CET/CEST
The... ► Artikel lesen | |
| CERENOME | 1,022 | -28,53 % | Cerenome Unit Signs National Reimbursement Agreement With Aetna; Shares Fall | ||
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | NuGen Medical Devices Inc.: NuGen Announces Loan Agreement with Sol-Millennium Medical HK Limited | Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce the entering into of a loan agreement (the "Loan Agreement")... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,120 | +1,92 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,028 | +6,92 % | CSE Bulletin: Reinstatement - UniDoc Health Corp. (UDOC) | Le 7 octobre/October 2026
Effective immediately, UniDoc Health Corp. will be reinstated for trading.
The Company has rectified the default situation that gave rise to the suspension.
__________________________
En... ► Artikel lesen | |
| TANDEM DIABETES | 16,300 | +3,16 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,385 | +1,32 % | Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India | CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile... ► Artikel lesen | |
| QUIDELORTHO | 11,630 | -7,81 % | QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54B | ||
| QUEST DIAGNOSTICS | 220,70 | 0,00 % | ROUNDUP: Quest Diagnostics Boosts FY26 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, diagnostic services firm Quest Diagnostics, Inc. (DGX) raised its earnings, adjusted earnings and... ► Artikel lesen | |
| VERU | 2,140 | -0,93 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data |